Astrotech (US:ASTC) Globenewswire·2025-09-25 20:35Core Insights - Astrotech Corporation reported a decrease in revenue to $1.0 million for the fiscal year ended June 30, 2025, compared to $1.664 million in the previous year, indicating a decline in device sales [4][9] - The gross margin improved slightly to 45.3% from 45.1% year-over-year, attributed to higher-margin device sales in fiscal year 2025 [4][9] - The company has expanded its international presence, deploying the TRACER 1000 in approximately 34 locations across 16 countries [4][3] Financial Performance - Total revenue for the fiscal year was $1,049,000, down from $1,664,000 in the previous year [9] - Operating expenses increased to $15.209 million from $14.031 million, with research and development expenses rising to $8.142 million from $6.790 million [9] - The net loss for the year was $13.850 million, compared to a net loss of $11.666 million in the prior year, resulting in a net loss per share of $8.32, up from $7.12 [9] Company Developments - Astrotech formed a new subsidiary, EN-SCAN, Inc., to manufacture and sell instruments for environmental testing applications [4][3] - The company launched the enhanced TRACER 1000 Narcotics Trace Detector, capable of rapid detection of narcotic compounds [4][3] - The first sale of the TRACER 1000 Narcotics Trace Detector occurred in Vietnam, marking a significant expansion into Southeast Asia [4][3] Balance Sheet Overview - As of June 30, 2025, the company had $18.2 million in cash and cash equivalents, which is expected to support organic growth and R&D [4] - Total assets decreased to $26.989 million from $37.640 million in the previous year, with current assets also declining significantly [11][12] - Total liabilities increased to $4.889 million from $2.833 million, while stockholders' equity fell to $22.100 million from $34.807 million [12]